1027371-75-0 Usage
Uses
Used in Bioconjugation:
C8H11NO5 is used as a PEG linker for bioconjugation to primary amines, enabling the attachment of various molecules to proteins, oligonucleotides, and other amine-containing molecules.
Used in Drug Delivery Systems:
C8H11NO5 is used as a PEG spacer in drug delivery systems to improve the solubility and stability of therapeutic agents in aqueous media.
Used in Diagnostics and Imaging:
C8H11NO5 is used as a PEG linker for the attachment of imaging agents or contrast agents to biomolecules, enhancing their visibility in diagnostic imaging techniques.
Used in Research and Development:
C8H11NO5 is used as a PEG linker in the development of new bioconjugates and molecular probes for research purposes, facilitating the study of molecular interactions and biological processes.
Check Digit Verification of cas no
The CAS Registry Mumber 1027371-75-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,2,7,3,7 and 1 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1027371-75:
(9*1)+(8*0)+(7*2)+(6*7)+(5*3)+(4*7)+(3*1)+(2*7)+(1*5)=130
130 % 10 = 0
So 1027371-75-0 is a valid CAS Registry Number.
1027371-75-0Relevant academic research and scientific papers
Rizvi, Syed Alipayam,Liu, Song,Chen, Zhonglei,Skau, Colleen,Pytynia, Matthew,Kovar, David R.,Chmura, Steven J.,Kozmin, Sergey A.
, p. 7288 - 7290 (2010)
We describe structure-based design and chemical synthesis of a simplified analog of bistramide A, which potently and reversibly binds monomeric actin with a Kd of 9.0 nM, depolymerizes filamentous actin in vitro and in A549 (nonsmall cell lung cancer) cells, inhibits growth of cancer cell lines in vitro at submicromolar concentrations, and significantly suppresses proliferation of A549 cells in a nude mice tumor xenograft model in terms of both tumor growth delay and average tumor volume. This study provides a conceptual framework for the design and development of new antiproliferative compounds that target cytoskeletal organization of cancer cells in vivo by a combination of reversible G-actin binding and effective F-actin severing.
